Utilization of oncotype DX in node-negative, ER-positive breast cancer patients

被引：0
|
作者：
Patel, H. [1 ]
Hook, K. [1 ]
Kaplan, C. [1 ]
Davidson, R. [1 ]
DeMichele, A. [1 ]
Fox, K. R. [1 ]
Domchek, S. M. [1 ]
机构：
[1] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11067
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer
    Wang, Fei
    Reid, Sonya
    Zheng, Wei
    Pal, Tuya
    Meszoely, Ingrid
    Mayer, Ingrid A.
    Bailey, Christina E.
    Park, Ben Ho
    Shu, Xiao-Ou
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 101 - 109
  • [22] Expression of Transcription Factors [FOXA1-GATA3] in ER-Positive Node-Negative Breast Cancer.
    Bohn, O. L.
    Carter, G.
    Brusky, A.
    Jankowitz, R.
    Badve, P.
    Chivukula, M.
    MODERN PATHOLOGY, 2011, 24 : 29A - 29A
  • [23] The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong
    Leung, Roland C. Y.
    Yau, Thomas C. C.
    Chan, Miranda C. M.
    Chan, Sharon W. W.
    Chan, Terence W. C.
    Tsang, Yvonne Y. Y.
    Wong, Ting Ting
    Chao, Calvin
    Yoshizawa, Carl
    Soong, Inda S.
    Kwan, Wing-Hong
    Kwok, Carol C. H.
    Suen, Joyce S. J.
    Ngan, Roger K. C.
    Cheung, Polly S. Y.
    CLINICAL BREAST CANCER, 2016, 16 (05) : 372 - 378
  • [24] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Andrew Dodson
    David Okonji
    Laura Assersohn
    Anne Rigg
    Amna Sheri
    Nick Turner
    Ian Smith
    Marina Parton
    Mitch Dowsett
    Breast Cancer Research and Treatment, 2018, 168 : 249 - 258
  • [25] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Dodson, Andrew
    Okonji, David
    Assersohn, Laura
    Rigg, Anne
    Sheri, Amna
    Turner, Nick
    Smith, Ian
    Parton, Marina
    Dowsett, Mitch
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 249 - 258
  • [26] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
  • [27] Evaluation of Oncotype DX as a predictor of nodal burden in clinically node negative breast cancer patients
    Tevis, Sarah
    Bedrosian, Isabelle
    Bassett, Roland
    FitzSullivan, Elizabeth
    Barcenas, Carlos
    Meric-Bernstam, Funda
    Hunt, Kelly
    Caudle, Abigail
    Kuerer, Henry
    Mittendorf, Elizabeth
    Thompson, Alastair
    Teshome, Mediget
    Lucci, Anthony
    DeSnyder, Sarah
    Black, Shon
    Park, Ko Un
    Hwang, Rosa
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 289 - 289
  • [28] Can the Ki67 Proliferation Index Predict the Oncotype DX Recurrence Score in Lymph Node Negative, ER Positive Breast Cancer?
    Prendergast, A.
    Martin, K.
    Doolan, P.
    Clarke, C.
    Clynes, M.
    Evoy, D.
    McDermott, E.
    Crown, J.
    Kennedy, S.
    CANCER RESEARCH, 2011, 71
  • [29] Impact of the Oncotype DX® Recurrence Score® Assay on therapy recommendations for ER-positive (ER+), node negative (N0) and node positive (N+) early breast cancer - Results of an interim analysis of the German decision impact study
    Blohmer, J. -U.
    Rezai, M.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I
    Eidtmann, H.
    Kaufmann, M.
    Eiermann, W.
    ONKOLOGIE, 2011, 34 : 119 - 120
  • [30] A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
    Fujii, Takeo
    Masuda, Hiroko
    Cheng, Yee Chung
    Yang, Fei
    Sahin, Aysegul A.
    Naoi, Yasuto
    Matsunaga, Yuki
    Raghavendra, Akshara Singareeka
    Sinha, Arup Kumar
    Fernandez, Jose R. Espinosa
    James, Anjali
    Yamagishi, Keisuke
    Matsushima, Tomoko
    Tripathy, Debu
    Tada, Sachiyo
    Jackson, Rubie S.
    Noguchi, Shinzaburo
    Nakamura, Seigo
    Acoba, Jared David
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345